High-throughput identification of functional regulatory SNPs in systemic lupus erythematosus.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
09 Aug 2024
Historique:
received: 14 08 2023
accepted: 17 07 2024
medline: 10 8 2024
pubmed: 10 8 2024
entrez: 9 8 2024
Statut: epublish

Résumé

Genome-wide association studies implicate multiple loci in risk for systemic lupus erythematosus (SLE), but few contain exonic variants, rendering systematic identification of non-coding variants essential to decoding SLE genetics. We utilized SNP-seq and bioinformatic enrichment to interrogate 2180 single-nucleotide polymorphisms (SNPs) from 87 SLE risk loci for potential binding of transcription factors and related proteins from B cells. 52 SNPs that passed initial screening were tested by electrophoretic mobility shift and luciferase reporter assays. To validate the approach, we studied rs2297550 in detail, finding that the risk allele enhanced binding to the transcription factor Ikaros (encoded by IKZF1), thereby modulating expression of IKBKE. Correspondingly, primary cells from genotyped healthy donors bearing the risk allele expressed higher levels of the interferon / NF-κB regulator IKKε. Together, these findings define a set of likely functional non-coding lupus risk variants and identify a regulatory pathway involving rs2297550, Ikaros, and IKKε implicated by human genetics in risk for SLE.

Identifiants

pubmed: 39122710
doi: 10.1038/s41467-024-50710-5
pii: 10.1038/s41467-024-50710-5
doi:

Substances chimiques

Ikaros Transcription Factor 148971-36-2
I-kappa B Kinase EC 2.7.11.10
IKZF1 protein, human 0
IKBKE protein, human EC 2.7.11.10
NF-kappa B 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6804

Subventions

Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
ID : 2R01AR065538
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
ID : R01AR075906
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
ID : R01AR073201
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
ID : P30AR070253

Informations de copyright

© 2024. The Author(s).

Références

Deapen, D. et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 35, 311–318 (1992).
pubmed: 1536669 doi: 10.1002/art.1780350310
Block, S. R. et al. Studies of twins with systemic lupus erythematosus. A review of the literature and presentation of 12 additional sets. Am. J. Med. 59, 533–552 (1975).
pubmed: 1101680 doi: 10.1016/0002-9343(75)90261-2
Alarcon-Segovia, D. et al. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum. 52, 1138–1147 (2005).
pubmed: 15818688 doi: 10.1002/art.20999
Vinuesa, C. G., Shen, N. & Ware, T. Genetics of SLE: mechanistic insights from monogenic disease and disease-associated variants. Nat. Rev. Nephrol. 19, 558–572 (2023).
Caielli, S., Wan, Z. & Pascual, V. Systemic lupus erythematosus pathogenesis: interferon and beyond. Annu Rev. Immunol. 41, 533–560 (2023).
pubmed: 36854182 doi: 10.1146/annurev-immunol-101921-042422
Zhang, H. et al. Meta-analysis of GWAS on both Chinese and European populations identifies GPR173 as a novel X chromosome susceptibility gene for SLE. Arthritis Res. Ther. 20, 92 (2018).
pubmed: 29724251 pmcid: 5934841 doi: 10.1186/s13075-018-1590-3
Morris, D. L. et al. Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus. Nat. Genet. 48, 940–946 (2016).
pubmed: 27399966 pmcid: 4966635 doi: 10.1038/ng.3603
Bentham, J. et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat. Genet. 47, 1457–1464 (2015).
pubmed: 26502338 pmcid: 4668589 doi: 10.1038/ng.3434
Langefeld, C. D. et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat. Commun. 8, 16021 (2017).
pubmed: 28714469 pmcid: 5520018 doi: 10.1038/ncomms16021
Gateva, V. et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat. Genet. 41, 1228–1233 (2009).
pubmed: 19838195 pmcid: 2925843 doi: 10.1038/ng.468
Westra, H. J. et al. Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes. Nat. Genet. 50, 1366–1374 (2018).
pubmed: 30224649 pmcid: 6364548 doi: 10.1038/s41588-018-0216-7
Butter, F. et al. Proteome-wide analysis of disease-associated SNPs that show allele-specific transcription factor binding. PLoS Genet. 8, e1002982 (2012).
pubmed: 23028375 pmcid: 3459973 doi: 10.1371/journal.pgen.1002982
Farh, K. K. et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518, 337–343 (2015).
pubmed: 25363779 doi: 10.1038/nature13835
Nicolae, D. L. et al. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet. 6, e1000888 (2010).
pubmed: 20369019 pmcid: 2848547 doi: 10.1371/journal.pgen.1000888
Perez, R. K. et al. Single-cell RNA-seq reveals cell type–specific molecular and genetic associations to lupus. Science 376, eabf1970 (2022).
pubmed: 35389781 pmcid: 9297655 doi: 10.1126/science.abf1970
Ulirsch, J. C. et al. Systematic functional dissection of common genetic variation affecting red blood cell traits. Cell 165, 1530–1545 (2016).
pubmed: 27259154 pmcid: 4893171 doi: 10.1016/j.cell.2016.04.048
Tewhey, R. et al. Direct identification of hundreds of expression-modulating variants using a multiplexed reporter assay. Cell 165, 1519–1529 (2016).
pubmed: 27259153 pmcid: 4957403 doi: 10.1016/j.cell.2016.04.027
Lu, X. et al. Global discovery of lupus genetic risk variant allelic enhancer activity. Nat. Commun. 12, 1611 (2021).
pubmed: 33712590 pmcid: 7955039 doi: 10.1038/s41467-021-21854-5
Li, G. et al. High-throughput identification of noncoding functional SNPs via type IIS enzyme restriction. Nat. Gene. 50, 1180–1188 (2018).
doi: 10.1038/s41588-018-0159-z
Wang, Q. et al. Identification of a regulatory pathway governing TRAF1 via an arthritis-associated non-coding variant. Cell Genom. 3, 100420 (2023).
pubmed: 38020975 pmcid: 10667332 doi: 10.1016/j.xgen.2023.100420
Karrar, S. & Cunninghame Graham, D. S. Abnormal B cell development in systemic lupus erythematosus: what the genetics tell us. Arthritis Rheumatol. 70, 496–507 (2018).
pubmed: 29207444 pmcid: 5900717 doi: 10.1002/art.40396
Bentham, J. et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat. Genet. 47, 1457–1464 (2015).
pubmed: 26502338 pmcid: 4668589 doi: 10.1038/ng.3434
Armstrong, D. L. et al. GWAS identifies novel SLE susceptibility genes and explains the association of the HLA region. Genes Immun. 15, 347–354 (2014).
pubmed: 24871463 pmcid: 4156543 doi: 10.1038/gene.2014.23
Hardenbol, P. & Van Dyke, M. W. Sequence specificity of triplex DNA formation: Analysis by a combinatorial approach, restriction endonuclease protection selection and amplification. Proc. Natl Acad. Sci. USA 93, 2811–2816 (1996).
pubmed: 8610123 pmcid: 39715 doi: 10.1073/pnas.93.7.2811
Trynka, G. et al. Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat. Genet. 45, 124–130 (2013).
pubmed: 23263488 doi: 10.1038/ng.2504
Rentzsch, P. et al. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 47, D886–d894 (2019).
pubmed: 30371827 doi: 10.1093/nar/gky1016
Miller, D. E. et al. Screening for functional non-coding genetic variants using electrophoretic mobility shift assay (EMSA) and DNA-affinity precipitation assay (DAPA). J. Vis. Exp. 54093 (2016).
Weirauch, M. T. et al. Evaluation of methods for modeling transcription factor sequence specificity. Nat. Biotechnol. 31, 126–134 (2013).
pubmed: 23354101 pmcid: 3687085 doi: 10.1038/nbt.2486
Weirauch, M. T. et al. Determination and inference of eukaryotic transcription factor sequence specificity. Cell 158, 1431–1443 (2014).
pubmed: 25215497 pmcid: 4163041 doi: 10.1016/j.cell.2014.08.009
Dvir, S. et al. Deciphering the rules by which 5′-UTR sequences affect protein expression in yeast. Proc. Natl Acad. Sci. USA 110, E2792–E2801 (2013).
pubmed: 23832786 pmcid: 3725075 doi: 10.1073/pnas.1222534110
Mignone, F. et al. Untranslated regions of mRNAs. Genome Biol. 3, reviews0004.1 (2002).
doi: 10.1186/gb-2002-3-3-reviews0004
Zhu, T. et al. The decreased expression of IKBKE in systemic lupus erythematosus. Clin. Rheumatol. 39, 2611–2617 (2020).
pubmed: 32146614 pmcid: 7426285 doi: 10.1007/s10067-020-05006-6
Wang, Y. F. et al. Identification of 38 novel loci for systemic lupus erythematosus and genetic heterogeneity between ancestral groups. Nat. Commun. 12, 772 (2021).
pubmed: 33536424 pmcid: 7858632 doi: 10.1038/s41467-021-21049-y
Kwon, Y. C. et al. Update on the genetics of systemic lupus erythematosus: genome-wide association studies and beyond. Cells 8, 1180 (2019).
pubmed: 31575058 pmcid: 6829439 doi: 10.3390/cells8101180
Wang, Q. et al. Identification of a regulatory pathway governing TRAF1 via an arthritis-associated non-coding variant. Cell Genom. 3, 100420 (2022).
Kim, T. et al. Non-coding autoimmune risk variant defines role for ICOS in T peripheral helper cell development. Nat Commun 15, 2150 (2024).
Chen, L., Morris, D. L. & Vyse, T. J. Genetic advances in systemic lupus erythematosus: an update. Curr. Opin. Rheumatol. 29, 423–433 (2017).
pubmed: 28509669 doi: 10.1097/BOR.0000000000000411
Pott, J. et al. Genetically regulated gene expression and proteins revealed discordant effects. PLoS ONE 17, e0268815 (2022).
pubmed: 35604899 pmcid: 9126407 doi: 10.1371/journal.pone.0268815
Robinson, J. W. et al. Evaluating the potential benefits and pitfalls of combining protein and expression quantitative trait loci in evidencing drug targets. Preprint at bioRxiv 2022.03.15.484248 (2022).
Gutierrez-Arcelus, M. et al. Allele-specific expression changes dynamically during T cell activation in HLA and other autoimmune loci. Nat. Genet. 52, 247–253 (2020).
pubmed: 32066938 pmcid: 7135372 doi: 10.1038/s41588-020-0579-4
Cytlak, U. et al. Ikaros family zinc finger 1 regulates dendritic cell development and function in humans. Nat. Commun. 9, 1239 (2018).
pubmed: 29588478 pmcid: 5869589 doi: 10.1038/s41467-018-02977-8
Clément, J. F., Meloche, S. & Servant, M. J. The IKK-related kinases: from innate immunity to oncogenesis. Cell Res. 18, 889–899 (2008).
pubmed: 19160540 doi: 10.1038/cr.2008.273
Fitzgerald, K. A. et al. IKKε and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4, 491–496 (2003).
pubmed: 12692549 doi: 10.1038/ni921
Tsukamoto, H. et al. Lipopolysaccharide (LPS)-binding protein stimulates CD14-dependent Toll-like receptor 4 internalization and LPS-induced TBK1–IKKϵ–IRF3 axis activation. J. Biol. Chem. 293, 10186–10201 (2018).
pubmed: 29760187 pmcid: 6028956 doi: 10.1074/jbc.M117.796631
Peters, R. T., Liao, S. M. & Maniatis, T. IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex. Mol. Cell 5, 513–522 (2000).
pubmed: 10882136 doi: 10.1016/S1097-2765(00)80445-1
Psarras, A., Wittmann, M. & Vital, E. M. Emerging concepts of type I interferons in SLE pathogenesis and therapy. Nat. Rev. Rheumatol. 18, 575–590 (2022).
pubmed: 36097207
Lafont, E. et al. TBK1 and IKKε prevent TNF-induced cell death by RIPK1 phosphorylation. Nat. Cell Biol. 20, 1389–1399 (2018).
pubmed: 30420664 pmcid: 6268100 doi: 10.1038/s41556-018-0229-6
Renner, F., Moreno, R. & Schmitz, M. L. SUMOylation-dependent localization of IKKepsilon in PML nuclear bodies is essential for protection against DNA-damage-triggered cell death. Mol. Cell 37, 503–515 (2010).
pubmed: 20188669 doi: 10.1016/j.molcel.2010.01.018
Kennedy, W. P. et al. Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. Lupus Sci. Med. 2, e000080 (2015).
pubmed: 25861459 pmcid: 4379884 doi: 10.1136/lupus-2014-000080
Akita, K. et al. Interferon α enhances B cell activation associated with FOXM1 induction: potential novel therapeutic strategy for targeting the plasmablasts of systemic lupus erythematosus. Front. Immunol. 11, 498703 (2021).
pubmed: 33633721 pmcid: 7902015 doi: 10.3389/fimmu.2020.498703
Wu, C. et al. Bioinformatics analysis of differentially expressed gene profiles associated with systemic lupus erythematosus. Mol. Med. Rep. 17, 3591–3598 (2018).
pubmed: 29257335
Romano, M. et al. Expanded regulatory T cells induce alternatively activated monocytes with a reduced capacity to expand T helper-17 cells. Front. Immunol. 9, 1625 (2018).
pubmed: 30079063 pmcid: 6062605 doi: 10.3389/fimmu.2018.01625
Heizmann, B., Kastner, P. & Chan, S. The Ikaros family in lymphocyte development. Curr. Opin. Immunol. 51, 14–23 (2018).
pubmed: 29278858 doi: 10.1016/j.coi.2017.11.005
Chen, L. et al. IKZF1 polymorphisms are associated with susceptibility, cytokine levels, and clinical features in systemic lupus erythematosus. Medicine 99, e22607 (2020).
pubmed: 33031316 pmcid: 7544280 doi: 10.1097/MD.0000000000022607
Han, J. W. et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat. Genet. 41, 1234–1237 (2009).
pubmed: 19838193 doi: 10.1038/ng.472
Cunninghame Graham, D. S. et al. Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet. 7, e1002341 (2011).
pubmed: 22046141 pmcid: 3203198 doi: 10.1371/journal.pgen.1002341
Wang, C. et al. Genes identified in Asian SLE GWASs are also associated with SLE in Caucasian populations. Eur. J. Hum. Genet. 21, 994–999 (2013).
pubmed: 23249952 doi: 10.1038/ejhg.2012.277
Vyse, T. J. & Cunninghame Graham, D. S. Trans-ancestral fine-mapping and epigenetic annotation as tools to delineate functionally relevant risk alleles at IKZF1 and IKZF3 in systemic lupus erythematosus. Int. J. Mol. Sci. 21, 8383 (2020).
pubmed: 33182226 pmcid: 7664943 doi: 10.3390/ijms21218383
Hoshino, A. et al. Abnormal hematopoiesis and autoimmunity in human subjects with germline IKZF1 mutations. J. Allergy Clin. Immunol. 140, 223–231 (2017).
pubmed: 27939403 doi: 10.1016/j.jaci.2016.09.029
Van Nieuwenhove, E. et al. A kindred with mutant IKAROS and autoimmunity. J. Allergy Clin. Immunol. 142, 699–702.e12 (2018).
pubmed: 29705243 pmcid: 6541477 doi: 10.1016/j.jaci.2018.04.008
Merrill, J. T. et al. Phase 2 trial of iberdomide in systemic lupus erythematosus. N. Engl. J. Med. 386, 1034–1045 (2022).
pubmed: 35294813 doi: 10.1056/NEJMoa2106535
Lipsky, P. E. et al. Biological impact of iberdomide in patients with active systemic lupus erythematosus. Ann. Rheum. Dis. 81, 1136–1142 (2022).
pubmed: 35477518 doi: 10.1136/annrheumdis-2022-222212
Wojcik, H. et al. Expression of a non-DNA-binding Ikaros isoform exclusively in B cells leads to autoimmunity but not leukemogenesis. Eur. J. Immunol. 37, 1022–1032 (2007).
pubmed: 17357110 doi: 10.1002/eji.200637026
Schwickert, T. A. et al. Ikaros prevents autoimmunity by controlling anergy and Toll-like receptor signaling in B cells. Nat. Immunol. 20, 1517–1529 (2019).
pubmed: 31591571 pmcid: 7115902 doi: 10.1038/s41590-019-0490-2
Allman, D. et al. Ikaros is required for plasmacytoid dendritic cell differentiation. Blood 108, 4025–4034 (2006).
pubmed: 16912230 pmcid: 1895449 doi: 10.1182/blood-2006-03-007757
Rivellese, F. et al. Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus. Lupus Sci. Med. 8, e000445 (2021).
pubmed: 33727237 pmcid: 7970264 doi: 10.1136/lupus-2020-000445
Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856–860 (2015).
pubmed: 26121088 doi: 10.1038/ng.3314
King, E. A., Davis, J. W. & Degner, J. F. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 15, e1008489 (2019).
pubmed: 31830040 pmcid: 6907751 doi: 10.1371/journal.pgen.1008489
Rentzsch, P. et al. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 47, D886–D894 (2018).
pmcid: 6323892 doi: 10.1093/nar/gky1016
Richardson, C. D. et al. Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat. Biotechnol. 34, 339–344 (2016).
pubmed: 26789497 doi: 10.1038/nbt.3481
Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543–D552 (2022).

Auteurs

Qiang Wang (Q)

Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Taehyeung Kim (T)

Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Marta Martínez-Bonet (M)

Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Laboratory of Immune-regulation, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.

Vitor R C Aguiar (VRC)

Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Sangwan Sim (S)

Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Jing Cui (J)

Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Jeffrey A Sparks (JA)

Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Xiaoting Chen (X)

Center of Autoimmune Genomics and Etiology, Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Marc Todd (M)

Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Brian Wauford (B)

Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Miranda C Marion (MC)

Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Center for Precision Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Carl D Langefeld (CD)

Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Center for Precision Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Matthew T Weirauch (MT)

Center of Autoimmune Genomics and Etiology, Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Divisions of Human Genetics, Biomedical Informatics, and Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Maria Gutierrez-Arcelus (M)

Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Peter A Nigrovic (PA)

Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. peter.nigrovic@childrens.harvard.edu.
Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. peter.nigrovic@childrens.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH